Research espionage

The Spy Next Door?

Academic institutions and government organizations strive to prevent research espionage while maintaining open scientific collaborations For decades, the U.S. has fostered international research collaborations with scientists in other countries, encouraging openness in hopes of better...

Online Exclusives

Trump Administration Considering Democratic Senator’s Drug Pricing Proposal

In early July, Senate Finance Committee Chairman Chuck Grassley (R-IA) met with Republican committee members to discuss a potential agreement that he and Sen....

Former VP Biden Wants to Usher in The Next Generation of...

Democratic presidential candidate and former Vice President Joe Biden released his health care plan, which primarily builds on the Affordable Care Act (ACA) while...

News

From the Blood Journals

WIB_icon

Equal Access to Treatment Erases Difference in Outcomes Between White and...

If African American patients with multiple myeloma (MM) are given equal access to treatments, they have outcomes that are as good as or better...
WIB_icon

Evaluating Safety and Efficacy of Venetoclax Plus R-CHOP in Non-Hodgkin Lymphoma

According to results from the phase Ib CAVALLI study, treatment with the oral BCL2 inhibitor venetoclax, combined with standard immunochemotherapy, induced high response rates...

Multimedia

Pulling Back the Curtain: Anna Schuh, MD, PhD

In more from our interview with Anna Schuh, MD, PhD, she shares her experiences volunteering with hematology patients in Tanzania.

Robert Kreitman: Delayed Versus Concurrent Rituximab in Hairy Cell Leukemia

Robert Kreitman, MD, shares results from a new study suggesting patients with hairy cell leukemia should receive rituximab concurrently with frontline cladribine.

Tibor Kovacsovics: CX-01 Associated With High Response Rates in Older Patients...

Tibor Kovacsovics, MD, discusses CX-01, a heparin derivative that induced high response rates in older patients newly diagnosed with acute myeloid leukemia.

Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma

Paul Richardson, MD, shares results seen with isatuximab in heavily refractory myeloma, and discusses how this new agent compares with approved monoclonal antibodies.

On Location

On location

AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma

In updated results from the first-in-human study of the bispecific T-cell engager (BITE) AMG 420,...
On location

Exploring New Settings for Tagraxofusp: CMML and Myelofibrosis

In late 2018, the U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of...
On location

Luteinizing Hormone Suppression Improves Post-Chemotherapy Hematopoietic Recovery in Patients With Leukemia

Treatment of leukemia with intensive chemotherapy increases patients’ risk of infection and bleeding due to...
On location

Bispecific Antibody REGN1979 Shows Promising Efficacy in Relapsed/Refractory Non-Hodgkin Lymphomas

In a small phase I study of patients with relapsed/refractory non-Hodgkin lymphoma (NHL), approximately half...
On location

Evaluating Rozanolixizumab in Primary Immune Thrombocytopenia

Rozanolixizumab, at doses ranging from 4 to 15 mg/kg, induced platelet responses in patients with...
On location

Dasatinib Plus Blinatumomab Increases Response and MRD Negativity in Ph-Positive Acute Lymphocytic Leukemia

Combining the second-generation tyrosine kinase inhibitor (TKI) dasatinib with the bispecific monoclonal antibody blinatumomab induced...

Latest Headlines

Advertisement

ASH Directions

ASH Directions

New ASH Congressional Fellow, Accepting Submissions for 2019 ASH Annual Meeting, and more

Next ASH Congressional Fellow Is Bound for Capitol Hill Zachary Kiser, PhD, has been selected by the American Society of Hematology (ASH) to be the...
ASH Directions

2020 Brings New Editor-in-Chief for ASH Clinical News, and more

Learn About Legislation and Health Policy from the ASH Advocacy Leadership Institute! This October marks the ninth annual ASH Advocacy Leadership Institute (ALI): An opportunity...

Sign up for our
eNewsletter!

The Society Pages

Steven Rosenberg Receives Szent-Györgyi Prize, FDA Names Elizabeth Jungman Head of Regulatory Policy, and...

Steven A. Rosenberg Receives Szent-Györgyi Prize The National Foundation for Cancer Research has awarded Steven A. Rosenberg, MD, PhD, the 2019 Szent-Györgyi Prize for Progress...
The Society Pages

Remembering Milton H. Freedman, Caryn Lerman Named Director of USC Norris, and More

Remembering Milton H. Freedman (1919 – 2019) Milton H. Freedman, MD, the first hematologist to open a private practice in Atlanta, died on January 21,...
The Society Pages

Remembering Arthur Rosenberg, Dorothy Tuan Lo, and more

Remembering Arthur Rosenberg (1935 – 2018) Arthur Rosenberg, MD, FRCPC, a former chief of hematology at the Jewish General Hospital (JGH) in Montreal, Quebec, passed...
Research espionage

The Spy Next Door?

Academic institutions and government organizations strive to prevent research espionage while maintaining open scientific collaborations For decades, the U.S. has fostered international research collaborations with...
In Myleloma, New Drugs, Skyrocketing Price Tags

In Myeloma, New Drugs, Skyrocketing Price Tags

In late February, seven pharmaceutical executives were called before the U.S. Senate Finance Committee to testify about the prices of brand-name prescription drugs, which...

Resurrecting the House Call

New at-home strategies for hematologic conditions offer improved outcomes and patient satisfaction Physician home visits have become a thing of the past: Nearly a century...